The following table summarizes expenses related to the Biogen Collaboration Agreement that were incurred by the Company and the related reimbursement from Biogen or to Biogen, reflected by category of operating expenses:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended June 30, |
|
|
Six Months Ended June 30, |
|
|
|
2023 |
|
|
2022 |
|
|
2023 |
|
|
2022 |
|
|
|
(in thousands) |
|
Expenses related to the Biogen Collaboration Agreement
incurred by Sage |
|
$ |
71,524 |
|
|
$ |
59,218 |
|
|
$ |
127,660 |
|
|
$ |
107,972 |
|
Net reimbursement to (from) Biogen reflected in the
condensed consolidated statements of operations and
comprehensive loss: |
|
|
|
|
|
|
|
|
|
|
|
|
Research and development expenses |
|
|
(22,418 |
) |
|
|
(20,983 |
) |
|
|
(39,700 |
) |
|
|
(39,497 |
) |
Selling, general and administrative expenses |
|
|
7,476 |
|
|
|
(2,835 |
) |
|
|
10,510 |
|
|
|
(4,309 |
) |
|
|
|
(14,942 |
) |
|
|
(23,818 |
) |
|
|
(29,190 |
) |
|
|
(43,806 |
) |
Total net expenses related to the Biogen Collaboration
Agreement in the condensed consolidated statements of
operations and comprehensive loss |
|
$ |
56,582 |
|
|
$ |
35,400 |
|
|
$ |
98,470 |
|
|
$ |
64,166 |
|
|